Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7-specific CAR-T in CD7+ R/R Hematologic Tumors
NCT06720324Phase 2Recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD7-specific CAR-T cells in hematologic neoplasms. Primary endpoints: Overall Response Rate at 3 years and Incidence of Treatment-related Adverse Events at 3 months. Started Dec 2024; status: recruiting.
02
Drugs
CD7-specific CAR-T cells
03
Conditions
hematologic neoplasms
Beyond the preview
Go deeper on NCT06720324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06720324.